Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Acquisitions & Divestments (2022 - 2025)

Amylyx Pharmaceuticals has reported Change in Acquisitions & Divestments over the past 4 years, most recently at $60.0 million for Q4 2025.

  • Quarterly results put Change in Acquisitions & Divestments at $60.0 million for Q4 2025, down 7.69% from a year ago — trailing twelve months through Dec 2025 was $246.0 million (down 28.49% YoY), and the annual figure for FY2025 was $246.0 million, down 28.49%.
  • Change in Acquisitions & Divestments for Q4 2025 was $60.0 million at Amylyx Pharmaceuticals, down from $64.0 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for AMLX hit a ceiling of $147.9 million in Q4 2023 and a floor of $24.9 million in Q1 2022.
  • Median Change in Acquisitions & Divestments over the past 4 years was $64.5 million (2024), compared with a mean of $72.7 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: soared 335.06% in 2023 and later crashed 56.06% in 2024.
  • Amylyx Pharmaceuticals' Change in Acquisitions & Divestments stood at $34.0 million in 2022, then soared by 335.06% to $147.9 million in 2023, then crashed by 56.06% to $65.0 million in 2024, then decreased by 7.69% to $60.0 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $60.0 million (Q4 2025), $64.0 million (Q3 2025), and $62.0 million (Q2 2025) per Business Quant data.